Low molecular weight heparin (LMWH) should be the preferred choice for preventing recurrent thromboembolism in patients with cancer, according to the results of a randomized trial reported in the Aug. 12/26 issue of the Archives of Internal Medicine. Patients receiving warfarin prophylaxis had higher rates of bleeding, recurrent thromboembolism, death from all causes and hemorrhagic death. No deaths from bleeding occurred in the LMWH group.
“The use of warfarin sodium for treating venous thromboembolism in patients with cancer is associated with a significant risk of recurrence and bleeding,” write Guy Meyer, MD, from the Hôpital Européen Georges Pompidou in Paris, France, and colleagues. “The use of LMWH sodium for secondary prevention of venous thromboembolism in cancer patients may reduce the complication rate.”
In this open-label, multicenter trial taking place between April 1995 and March 1999, 146 patients with venous thromboembolism and cancer were randomized to three months of treatment with the LMWH subcutaneous enoxaparin sodium, 1.5 mg/kg once a day, or with warfarin. A combined outcome event was defined as major bleeding or recurrent venous thromboembolism within three months.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!